Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6831)
All Articles published online
|
Publishing Process of This Article
|
Feb 28, 2013 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 2013; 19(8): 1318-1321 [PMID: 23483799 DOI: 10.3748/wjg.v19.i8.1318] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i8/1318.htm |
| Number | Citing Articles |
| 1 |
Stevan A. Gonzalez, Robert P. Perrillo. Hepatitis B Virus in Human Diseases. Molecular and Translational Medicine 2016; : 399 doi: 10.1007/978-3-319-22330-8_18
|
| 2 |
Rohit Loomba, T. Jake Liang. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology 2017; 152(6): 1297 doi: 10.1053/j.gastro.2017.02.009
|
| 3 |
Venessa Pattullo. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clinical and Molecular Hepatology 2016; 22(2): 219 doi: 10.3350/cmh.2016.0024
|
| 4 |
Jun Cheng, Jinjin Pan, Dongmei Zhao, Xuejiao Ma, Qiulin Sun, Jiabin Li. HCV Reactivation in a Patient with Hepatocellular Carcinoma Due to Sorafenib: A Case Report. International Medical Case Reports Journal 2024; : 121 doi: 10.2147/IMCRJ.S444521
|
| 5 |
Mar Riveiro-Barciela, Paula Gubern, Luisa Roade, Pau Abrisqueta, María José Carreras, Anna Farriols, Francesc Bosch, Rafael Esteban, María Buti. An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-59476-4
|
| 6 |
Ling‐Yi Wang, Sung‐Chao Chu, I‐Yun Chang, K. Arnold Chan. Sex‐specific incidence of hepatitis B virus flares among Bcr‐Abl tyrosine kinase inhibitor users in Taiwan. Pharmacoepidemiology and Drug Safety 2023; 32(12): 1368 doi: 10.1002/pds.5667
|
| 7 |
Toshihiko Ando, Kensuke Kojima, Hiroshi Isoda, Yuichiro Eguchi, Takashi Honda, Masatoshi Ishigami, Shinya Kimura. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. International Journal of Hematology 2015; 102(3): 379 doi: 10.1007/s12185-015-1788-y
|
| 8 |
Gian Paolo Caviglia, Antonella Zorzi, Mario Rizzetto, Massimo Mirandola, Antonella Olivero, Giada Carolo. Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. Diagnostics 2021; 11(12): 2185 doi: 10.3390/diagnostics11122185
|
| 9 |
Yu-Hung Wang, Ja-Der Liang, Wang-Huei Sheng, Feng-Ming Tien, Chien-Yuan Chen, Hwei-Fang Tien. Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemia. Leukemia Research 2019; 81: 95 doi: 10.1016/j.leukres.2019.05.001
|
| 10 |
Andreas Panagopoulos, Stavros Taraviras, Hideo Nishitani, Zoi Lygerou. CRL4Cdt2: Coupling Genome Stability to Ubiquitination. Trends in Cell Biology 2020; 30(4): 290 doi: 10.1016/j.tcb.2020.01.005
|
| 11 |
Bee Kim Tan, Siew Siang Chua, Li-Chia Chen, Kian Meng Chang, Sharmini Balashanker, Ping Chong Bee. Acceptability of pharmacist-led interventions to resolve drug-related problems in patients with chronic myeloid leukaemia. Journal of Oncology Pharmacy Practice 2021; 27(7): 1644 doi: 10.1177/1078155220964539
|
| 12 |
Robert P. Perrillo, Robert Gish, Yngve T. Falck-Ytter. American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology 2015; 148(1): 221 doi: 10.1053/j.gastro.2014.10.038
|
| 13 |
Christos Koutsianas, Konstantinos Thomas, Dimitrios Vassilopoulos. Hepatitis B Reactivation in Rheumatic Diseases. Rheumatic Disease Clinics of North America 2017; 43(1): 133 doi: 10.1016/j.rdc.2016.09.012
|
| 14 |
L. Sarmati, M. Andreoni, G. Antonelli, W. Arcese, R. Bruno, N. Coppola, G.B. Gaeta, M. Galli, C. Girmenia, M. Mikulska, F. Pane, C.F. Perno, M. Picardi, M. Puoti, A. Rambaldi, V. Svicher, G. Taliani, G. Gentile. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. Clinical Microbiology and Infection 2017; 23(12): 935 doi: 10.1016/j.cmi.2017.06.023
|
| 15 |
Tuncer Temel, Eren Gunduz, Esmira Sadigova, Hava Uskudar Teke, Safak Meric Ozgenel, Aysegul Harmanci Ozakyol. Hepatitis B Virus Reactivation under
Treatment with Nilotinib. Euroasian Journal of Hepato-Gastroenterology 2015; 5(2): 112 doi: 10.5005/jp-journals-10018-1147
|
| 16 |
M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi, J.M. Aguado. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clinical Microbiology and Infection 2018; 24: S53 doi: 10.1016/j.cmi.2018.02.009
|
| 17 |
Alessandra Tedeschi, Anna Maria Frustaci, Maddalena Mazzucchelli, Roberto Cairoli, Marco Montillo. Is HBV prophylaxis required during CLL treatment with ibrutinib?. Leukemia & Lymphoma 2017; 58(12): 2966 doi: 10.1080/10428194.2017.1317094
|
| 18 |
Shang-Chin Huang, Hung-Chih Yang, Jia-Horng Kao. Hepatitis B reactivation: diagnosis and management. Expert Review of Gastroenterology & Hepatology 2020; 14(7): 565 doi: 10.1080/17474124.2020.1774364
|
| 19 |
Xiaoming Cheng, Takuro Uchida, Yuchen Xia, Regina Umarova, Chun-Jen Liu, Pei-Jer Chen, Anuj Gaggar, Vithika Suri, Marcus M. Mücke, Johannes Vermehren, Stefan Zeuzem, Yuji Teraoka, Mitsutaka Osawa, Hiroshi Aikata, Keiji Tsuji, Nami Mori, Shuhei Hige, Yoshiyasu Karino, Michio Imamura, Kazuaki Chayama, T. Jake Liang. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. Journal of Clinical Investigation 2020; 130(6): 3205 doi: 10.1172/JCI135616
|
| 20 |
Venessa Pattullo. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World Journal of Hepatology 2015; 7(7): 954-967 doi: 10.4254/wjh.v7.i7.954
|
| 21 |
Muhsin Kaya, Recai Akdogan, Feyzullah Uçmak, Mehmet O Ayyildiz, Abdullah Karakus, Muhammet A Kaplan. The Incidence and Predictive Factors in the Development of Acute Hepatitis in Patients with Leukemia. Euroasian Journal of Hepato-Gastroenterology 2018; 8(1): 31 doi: 10.5005/jp-journals-10018-1254
|
| 22 |
Tian Yu, Weiming Li, Tao Yu. Management of chronic myelogenous leukemia with COVID-19 and hepatitis B. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1217023
|
| 23 |
Kirsty Wai-Chung Lee, Stephen Lam Chan. Hepatotoxicity of targeted therapy for cancer. Expert Opinion on Drug Metabolism & Toxicology 2016; 12(7): 789 doi: 10.1080/17425255.2016.1190831
|
| 24 |
Shady Adnan Awad, Matti Kankainen, Teija Ojala, Perttu Koskenvesa, Samuli Eldfors, Bishwa Ghimire, Ashwini Kumar, Soili Kytölä, Mahmoud M. Kamel, Caroline A. Heckman, Kimmo Porkka, Satu Mustjoki. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Advances 2020; 4(3): 546 doi: 10.1182/bloodadvances.2019000943
|
| 25 |
Ling-Yi Wang, Sung-Chao Chu, Yin Lo, Yen-Yun Yang, K. Arnold Chan. Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan. JAMA Network Open 2021; 4(4): e214132 doi: 10.1001/jamanetworkopen.2021.4132
|
| 26 |
Federica Sorà, Francesca Romana Ponziani, Luca Laurenti, Patrizia Chiusolo, Francesco Autore, Antonio Gasbarrini, Simona Sica, Maurizio Pompili. Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia & Lymphoma 2017; 58(4): 993 doi: 10.1080/10428194.2016.1219906
|
| 27 |
Lidan Hou, Jie Zhao, Shaobing Gao, Tong Ji, Tianyu Song, Yining Li, Jingjie Wang, Chenlu Geng, Min Long, Jiang Chen, Hui Lin, Xiujun Cai, Yong Cang. Restriction of hepatitis B virus replication by c-Abl–induced proteasomal degradation of the viral polymerase. Science Advances 2019; 5(2) doi: 10.1126/sciadv.aau7130
|
| 28 |
Asmaa Atteya, Aiman Ahmad, Dima Daghstani, Kamran Mushtaq, Mohamed A. Yassin. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 2020; 27(1) doi: 10.1177/1073274820976594
|
| 29 |
Young Chang, Soung Won Jeong, Jae Young Jang. Hepatitis B Virus Reactivation Associated With Therapeutic Interventions. Frontiers in Medicine 2022; 8 doi: 10.3389/fmed.2021.770124
|
| 30 |
S. Yazaki, T. Yamauchi, T. Higashi. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan. International Journal of Clinical Oncology 2020; 25(7): 1327 doi: 10.1007/s10147-020-01655-4
|
| 31 |
Bettina M. Knoll, K. Seiter. Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature. Infection 2018; 46(3): 409 doi: 10.1007/s15010-017-1105-1
|
| 32 |
Mark Reinwald, Tobias Boch, Wolf-Karsten Hofmann, Dieter Buchheidt. Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights 2015; : BMI.S22430 doi: 10.4137/BMI.S22430
|
| 33 |
Mauro Viganò, Giuseppe Serra, Giovanni Casella, Glenda Grossi, Pietro Lampertico. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opinion on Biological Therapy 2016; 16(7): 917 doi: 10.1080/14712598.2016.1177017
|
| 34 |
Ester Maria Orlandi, Chiara Elena, Elisa Bono. Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia. Leukemia & Lymphoma 2017; 58(7): 1764 doi: 10.1080/10428194.2016.1260127
|
| 35 |
Oscar Marchetti, Frederic Tissot, Thierry Calandra. Infectious Diseases. 2017; : 723 doi: 10.1016/B978-0-7020-6285-8.00079-4
|
| 36 |
Faisal Inayat, Fei Song, Nouman Safdar Ali, Muhammad Haseeb Aslam, Aishatu Aloma, Hilal Hachem, Muhammad Wasif Saif. Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases. Journal of Oncology Pharmacy Practice 2019; 25(6): 1500 doi: 10.1177/1078155218790337
|
| 37 |
Giuseppe Indolfi, Mona Abdel‐Hady, Sanjay Bansal, Dominique Debray, Françoise Smets, Piotr Czubkowski, Wendy van der Woerd, Marianne Samyn, Jörg Jahnel, Girish Gupte, Aglaia Zellos, Yael Mozer‐Glassberg, Henkjan J. Verkade, Etienne Sokal, Björn Fischler. Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. Journal of Pediatric Gastroenterology and Nutrition 2020; 70(4): 527 doi: 10.1097/MPG.0000000000002628
|
| 38 |
Sarah Atkins, Fiona He. Chemotherapy and Beyond. Infectious Disease Clinics of North America 2019; 33(2): 289 doi: 10.1016/j.idc.2019.01.001
|
| 39 |
Delphine Rea. Chronic Myeloid Leukemia. Hematologic Malignancies 2021; : 77 doi: 10.1007/978-3-030-71913-5_6
|
| 40 |
|
| 41 |
Jian Li, Ming Wang, Bo Zhang, Xin Wu, Tian-Long Lin, Xiu-Feng Liu, Ye Zhou, Xin-Hua Zhang, Hao Xu, Li-Jing Shen, Jing Zou, Ping Lu, Dong Zhang, Wei-Jun Gu, Mei-Xia Zhang, Jian Pan, Hui Cao, Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World Journal of Gastroenterology 2018; 24(46): 5189-5202 doi: 10.3748/wjg.v24.i46.5189
|
| 42 |
Ka-Shing Cheung, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatology International 2016; 10(3): 407 doi: 10.1007/s12072-015-9692-3
|
| 43 |
Mansour Tobaiqy, Nawal Helmi, Katie MacLure, Sylvia Saade. The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review. International Journal of Clinical Pharmacy 2024; 46(2): 368 doi: 10.1007/s11096-023-01671-0
|
| 44 |
Man Fai Law, Rita Ho, Carmen KM Cheung, Lydia HP Tam, Karen Ma, Kent CY So, Bonaventure Ip, Jacqueline So, Jennifer Lai, Joyce Ng, Tommy HC Tam. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World Journal of Gastroenterology 2016; 22(28): 6484-6500 doi: 10.3748/wjg.v22.i28.6484
|
| 45 |
Ivan Noreña, Mario Fernández-Ruiz, José María Aguado. Viral infections in the biologic therapy era. Expert Review of Anti-infective Therapy 2018; 16(10): 781 doi: 10.1080/14787210.2018.1521270
|
| 46 |
C.S. Voican, O. Mir, P. Loulergue, M. Dhooge, C. Brezault, J. Dréanic, S. Chaussade, S. Pol, R. Coriat. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Annals of Oncology 2016; 27(12): 2172 doi: 10.1093/annonc/mdw414
|
| 47 |
Maria V. Konopleva, Maxim S. Belenikin, Andrei V. Shanko, Alexey I. Bazhenov, Sergei A. Kiryanov, Tatyana A. Tupoleva, Maria V. Sokolova, Alexander V. Pronin, Tatyana A. Semenenko, Anatoly P. Suslov. Detection of S-HBsAg Mutations in Patients with Hematologic Malignancies. Diagnostics 2021; 11(6): 969 doi: 10.3390/diagnostics11060969
|
| 48 |
Akimasa Sanagawa, Yuji Hotta, Tomoya Kataoka, Yasuhiro Maeda, Masahiro Kondo, Yoshihiro Kawade, Yoshihiro Ogawa, Ryohei Nishikawa, Masahiro Tohkin, Kazunori Kimura. Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer Medicine 2018; 7(6): 2269 doi: 10.1002/cam4.1429
|
| 49 |
Hidekazu Itamura, Yasushi Kubota, Takero Shindo, Toshihiko Ando, Kensuke Kojima, Shinya Kimura. Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg. Clinical Lymphoma Myeloma and Leukemia 2017; 17(6): 370 doi: 10.1016/j.clml.2017.02.023
|
| 50 |
Christos Koutsianas, Konstantinos Thomas, Dimitrios Vassilopoulos. Prevention of HBV reactivation in patients treated with biologic agents. Expert Review of Clinical Pharmacology 2016; 9(4): 579 doi: 10.1586/17512433.2016.1143773
|
| 51 |
Sirina Ekpanyapong, K. Rajender Reddy. Hepatitis B Virus Reactivation. Clinics in Liver Disease 2020; 24(3): 317 doi: 10.1016/j.cld.2020.04.002
|
| 52 |
Cheng-Shyong Chang, Chien-Yu Tsai, Sheng-Lei Yan. Hepatitis B reactivation in patients receiving targeted therapies. Hematology 2017; 22(10): 592 doi: 10.1080/10245332.2017.1321882
|
| 53 |
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye, Michael Boyle. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 2020; 33(3) doi: 10.1128/CMR.00035-19
|
| 54 |
Wai-Kay Seto. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World Journal of Hepatology 2015; 7(6): 825-830 doi: 10.4254/wjh.v7.i6.825
|
| 55 |
Clement Chun-Ho Wu, Rajneesh Kumar. Hepatitis B reactivation in patients with hepatitis B core antibody positive and surface antigen negative on immunosuppressants. World Journal of Meta-Analysis 2019; 7(5): 209-217 doi: 10.13105/wjma.v7.i5.209
|